Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017

Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017


  • Products Id :- GDHC4403CTIDB
  • |
  • Pages: 166
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, "Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017" provides an overview of Duchenne Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Duchenne Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 14

Top Countries Contributing to Clinical Trials in Middle East and Africa 15

Top Countries Contributing to Clinical Trials in Central and South America 16

Clinical Trials by G7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials 17

Clinical Trials by Phase in G7 Countries 19

Clinical Trials in G7 Countries by Trial Status 20

Clinical Trials by E7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials 22

Clinical Trials by Phase in E7 Countries 24

Clinical Trials in E7 Countries by Trial Status 25

Clinical Trials by Phase 26

In Progress Trials by Phase 27

Clinical Trials by Trial Status 28

Clinical Trials by End Point Status 30

Subjects Recruited Over a Period of Time 31

Clinical Trials by Sponsor Type 32

Prominent Sponsors 33

Top Companies Participating in Duchenne Muscular Dystrophy Therapeutics Clinical Trials 35

Prominent Drugs 37

Latest Clinical Trials News on Duchenne Muscular Dystrophy 38

Jul 18, 2017: PTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet 38

Jun 26, 2017: Antisense Therapeutics to Enter Clinical Development in Duchenne Muscular Dystrophy 38

Jun 23, 2017: Catabasis Pharmaceuticals to Present Results from the MoveDMD Trial of Edasalonexent at the 2017 PPMD Annual Connect Conference 39

Jun 22, 2017: Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress 39

Jun 22, 2017: New Analyses of Translarna (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress 39

Jun 14, 2017: CureDuchenne to Host Webinar with Santhera Pharmaceuticals on SIDEROS Trial 40

May 30, 2017: Pfizer Completes Enrollment of Phase 2 Study of Domagrozumab (PF- 06252616) in Duchenne Muscular Dystrophy 40

May 23, 2017: New Analysis of ACT DMD Placebo Data on Corticosteroids Presented at International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting 40

May 16, 2017: Santhera to Present Data and Host Symposium on Pulmonary Function in Duchenne Muscular Dystrophy at the American Thoracic Society 113th Annual Conference 40

May 15, 2017: Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD 41

May 11, 2017: New Preclinical Data Support SGT-001 As A Novel Treatment Approach For Duchenne Muscular Dystrophy 42

May 03, 2017: GTx Announces Results from Preclinical Studies of SARMs in Duchenne Muscular Dystrophy Models Published in Human Molecular Genetics 42

Clinical Trial Profile Snapshots 43

Appendix 164

Abbreviations 164

Definitions 164

Research Methodology 165

Secondary Research 165

About GlobalData 166

Contact Us 166

Source 166

List of Figures

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region (%), 2017* 8

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 16

Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 17

Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19

Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20

Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 22

Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24

Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase (%), 2017* 26

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 27

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31

Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 32

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

GlobalData Methodology 165

List of Tables

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region, 2017* 8

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries, 2017* 14

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 16

Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 18

Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19

Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 21

Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 23

Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24

Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase, 2017* 26

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 27

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31

Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 32

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

BioMarin Pharmaceutical Inc

PTC Therapeutics Inc

Sarepta Therapeutics Inc

Marathon Pharmaceuticals LLC

GlaxoSmithKline Plc

Summit Therapeutics Plc

Akashi Therapeutics Inc

Prosensa Holding B.V.

CureDuchenne

Catabasis Pharmaceuticals Inc

Duchenne Muscular Dystrophy Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Duchenne Muscular Dystrophy, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania

select a license

Single User License
USD 2500 INR 160900
Site License
USD 5000 INR 321800
Corporate User License
USD 7500 INR 482700

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com